VEGPF News Alert Vectura Group Plc (VEGPF) 2.1000 10/01/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Vectura Group Plc (VEGPF) 2.1000 $VEGPF

Global Chronic Cough Therapeutics Pipeline Review 2014 - 7 Companies & 7 Drug Profiles
M2 - Tue Sep 16, 8:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hx29h3/chronic_cough) has announced the addition of the "Chronic Cough - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Cough, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Cough and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - GlaxoSmithKline plc - Vectura Group plc - Glenmark Pharmaceuticals Ltd. - OPKO Health, Inc. - Afferent Pharmaceuticals, Inc. - Cerecor Inc. - Ario Pharma Ltd Drug Profiles - SCH-900978 - XEND-0501 - AF-219 - GRC-17536 - memantine hydrochloride - GSK-2339345 - VR-611 For more information visit http://www.researchandmarkets.com/research/hx...onic_cough

Lung Transplantation - Pipeline Review, H1 2014 Research Report
M2 - Mon Feb 24, 3:19AM CST
Research and Markets (http://www.researchandmarkets.com/research/lhlntx/lung) has announced the addition of the "Lung Transplantation - Pipeline Review, H1 2014" report to their offering. 'Lung Transplantation - Pipeline Review, H1 2014', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Lung Transplantation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Lung Transplantation. Scope - A snapshot of the global therapeutic scenario for Lung Transplantation. - A review of the Lung Transplantation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Lung Transplantation pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: List of Tables List of Figures Introduction Lung Transplantation Overview Therapeutics Development Pipeline Products for Lung Transplantation - Overview Pipeline Products for Lung Transplantation - Comparative Analysis Lung Transplantation - Therapeutics under Development by Companies Lung Transplantation - Pipeline Products Glance Late Stage Products Early Stage Products Lung Transplantation - Companies Involved in Therapeutics Development Lung Transplantation - Therapeutics Assessment Drug Profiles cyclosporine - Drug Profile EZ-2053 - Drug Profile Elafin - Drug Profile Respiratory and Inflammatory Diseases Program - Drug Profile VR-909 - Drug Profile Lung Transplantation - Recent Pipeline Updates Lung Transplantation - Product Development Milestones Featured News & Press Releases Appendix List of Tables List of Figures Companies Mentioned Quark Pharmaceuticals, Inc. Vectura Group plc Proteo, Inc. APT Pharmaceuticals, Inc. (Inactive) Neopharm Ltd. For more information visit http://www.researchandmarkets.com/research/lhlntx/lung About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H2 2013
M2 - Tue Sep 03, 8:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/w94m9s/chronic) has announced the addition of the "Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H2 2013" report to their offering. 'Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Chronic Obstructive Pulmonary Disease (COPD), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Chronic Obstructive Pulmonary Disease (COPD). Scope - A snapshot of the global therapeutic scenario for Chronic Obstructive Pulmonary Disease (COPD). - A review of the Chronic Obstructive Pulmonary Disease (COPD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Chronic Obstructive Pulmonary Disease (COPD) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Johnson & Johnson Boehringer Ingelheim GmbH Kyowa Hakko Kirin Co., Ltd. Osiris Therapeutics, Inc. EpiGenesis Pharmaceuticals, Inc. Amgen Inc. AstraZeneca PLC GlaxoSmithKline plc MedImmune LLC Merck & Co., Inc. Dainippon Sumitomo Pharma Co., Ltd. Bioneer Corporation Vectura Group plc Pearl Therapeutics, Inc. Nycomed International Management GmbH Novartis AG ASKA Pharmaceutical Co., Ltd Chiesi Farmaceutici SpA Dong-A Pharmaceutical Co., Ltd. Glenmark Pharmaceuticals Ltd. Kissei Pharmaceutical Co., Ltd. Laboratoires Pierre Fabre SA Meda AB Orion Corporation and many more... For more information visit http://www.researchandmarkets.com/research/w94m9s/chronic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Transplantation - Pipeline Review, H2 2013
M2 - Mon Sep 02, 9:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/s2563g/transplantation) has announced the addition of the "Transplantation - Pipeline Review, H2 2013" report to their offering. 'Transplantation - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Transplantation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Transplantation. Scope - A snapshot of the global therapeutic scenario for Transplantation. - A review of the Transplantation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Transplantation pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Hospira, Inc. F. Hoffmann-La Roche Ltd. Kyowa Hakko Kirin Co., Ltd. Osiris Therapeutics, Inc. Athersys, Inc. GlaxoSmithKline plc Quark Pharmaceuticals, Inc. Merck & Co., Inc. AbGenomics International, Inc. Emergent BioSolutions Inc. Oxford BioMedica plc Pharming Group N.V. Vectura Group plc BioLineRx, Ltd. Novartis AG Isotechnika Pharma Inc. Samyang Corporation Astellas Pharma Inc. ViroPharma Incorporated Cell Therapeutics, Inc. Genmab A/S Exelixis, Inc. and many more... For more information visit http://www.researchandmarkets.com/research/s2...plantation About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Global Pulmonary Drug Delivery Systems Market 2012-2016: Intense Competition a Major Challenge Faced By the Market
M2 - Tue Jul 30, 6:17AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mf9vgx/global_pulmonary) has announced the addition of the "Global Pulmonary Drug Delivery Systems Market 2012-2016" report to their offering. The analysts forecast the Global Pulmonary Drug Delivery Systems market to grow at a CAGR of 14.47 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing incidence of lung-related or respiratory diseases. The Global Pulmonary Drug Delivery Systems market has also been witnessing an increasing adoption of online marketing strategy. However, intense competition among vendors could pose a challenge to the growth of this market. Commenting on the report, an analyst from the team said: The Global Pulmonary Drug Delivery Systems market is highly fragmented with a large number of vendors having significant market shares. These vendors range from large corporations producing a broad range of advanced and premium pulmonary drug delivery systems on a worldwide scale to small and medium-sized companies that concentrate on a single product line in a specific geographic region. Further, there is strong competition from cheaper private label products also. The leading vendors are presently working on low profit because of strong competition. Moreover, there is severe pricing pressure, which leads to a reduction in vendors' profit margins. Thus, intense competition is a major challenge faced by the market, and it is expected to pose a strong challenge to the market growth during the forecast period. According to the report, one of the major drivers is the increasing prevalence of lung-related or respiratory diseases such as asthma and COPD across the globe. It is estimated that around 300 million people are suffering from asthma. This influences the market for pulmonary drug delivery inhalation devices. Companies Mentioned - 3M Healthcare Ltd. - Akela Pharma Inc. - Alkermes Inc. - Allied Healthcare Products Inc. - AstraZeneca plc - Boehringer Ingelheim GmbH - CareFusion Corp. - Chiesi Farmaceutici S.p.A. - Dainippon Sumitomo Pharma Co. Ltd. - GF Health Products Inc. - GlaxoSmithKline plc - Novartis AG - Omron Healthcare Co. Ltd. - PARI Respiratory Equipment Inc. - Philips Respironics Inc. - SkyePharma plc - Sunovion Pharmaceuticals Inc. - Vectura Group plc. For more information visit http://www.researchandmarkets.com/research/mf..._pulmonary About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Lung Transplantation - Pipeline Review, H1 2013
M2 - Fri Apr 12, 5:28AM CDT
Research and Markets has announced the addition of the "Lung Transplantation - Pipeline Review, H1 2013" report to their offering. 'Lung Transplantation - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Lung Transplantation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Lung Transplantation. Scope - A snapshot of the global therapeutic scenario for Lung Transplantation. - A review of the Lung Transplantation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Lung Transpl

Erectile Dysfunction - Pipeline Review, H1 2013
M2 - Mon Mar 25, 9:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hp2gn2/erectile) has announced the addition of the "Erectile Dysfunction - Pipeline Review, H1 2013" report to their offering. Global Markets Direct's, 'Erectile Dysfunction - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Erectile Dysfunction, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Erectile Dysfunction. Scope - A snapshot of the global therapeutic scenario for Erectile Dysfunction. - A review of the Erectile Dysfunction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline proje

Premature Ejaculation - Pipeline Review, H1 2013
M2 - Thu Mar 21, 3:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tpptkh/premature) has announced the addition of the "Premature Ejaculation - Pipeline Review, H1 2013" report to their offering. Global Markets Direct's, 'Premature Ejaculation - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Premature Ejaculation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Premature Ejaculation. Scope - A snapshot of the global therapeutic scenario for Premature Ejaculation. - A review of the Premature Ejaculation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipelin

Migraine - Pipeline Review, H1 2013
M2 - Tue Mar 12, 7:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wqgjw4/migraine) has announced the addition of Global Markets Direct's new report "Migraine - Pipeline Review, H1 2013" to their offering. Global Markets Direct's, 'Migraine - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Migraine, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Migraine. Migraine - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Migraine. - A review of the Mi

Cystic Fibrosis - Pipeline Review, H2 2012
M2 - Tue Jan 08, 4:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/p9x3z6/cystic_fibrosis) has announced the addition of Global Markets Direct's new report "Cystic Fibrosis - Pipeline Review, H2 2012" to their offering. 'Cystic Fibrosis - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Cystic Fibrosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cystic Fibrosis. Scope - A snapshot of the global therapeutic scenario for Cystic Fibrosis. - A review of the Cystic Fibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monothe




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Employer Ghosting Is a Quiet Talent-Cost Problem Today

Updated Category News Views 232

Silence is cheap right up until a company needs talent again. Then the unanswered email, abandoned interview loop, or vanished promise of next steps comes back with a price tag—maybe not neatly labeled in a quarterly filing, but real all the same. LiveCareer’s April 14, 2026 survey of 1,008 employed U.S. adults lands on an uncomfortable point: candidates remember...

Continue Reading
Kinross Lawsuit Puts Round Mountain Claims Under Fire

Updated Category News Views 128

A mine can swallow a rosy forecast faster than any spreadsheet admits. That is the ugly center of the proposed securities class action involving Kinross Gold: not merely that production guidance came down, but the allegation that investors were sold too much confidence before the operational reality at Round Mountain Phase S surfaced. NYSE:KGC dropped from $27.62 on...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 187

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 217

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
WaterField’s Nova Case Bets on Better Handheld Carry

Updated Category News Views 302

Tiny handhelds have spawned a surprisingly fussy luggage problem: protection without the clown-show aesthetic. WaterField Designs is taking a clean swing at that with a custom case for the Retroid Pocket Nova, a sleeve-like carrier built around the device rather than some generic pouch that leaves everything rattling around inside. This is not a market-moving corporate...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 183

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 119

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 154

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 169

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 187

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading

Top 5 Most Recently Viewed Articles

Community Engagement Takes Center Stage at SAS Championship

Updated Category News Views 196

Community Engagement Takes Center Stage at SAS Championship Community initiative supports local teachers, sparks student interest in technology Teachers often face financial challenges covering classroom needs, especially in STEM (science, technology, engineering, and math) education, which is critical for preparing students for a tech-driven future. To alleviate this,...

Continue Reading
Explore Yaber's Next-Gen Projectors Unveiled at CES 2025

Updated Category News Views 305

Innovative Projectors Unveiled by Yaber at CES 2025 Yaber, renowned for its cutting-edge entertainment projectors, revealed its latest models at the CES 2025 event. Among these, the K300s, L2 Plus, and T2 Series stand out, showcasing incredible advancements in home entertainment technology. These projectors are designed to elevate the viewing experience, whether you're...

Continue Reading
Important Update for UroGen Pharma Investors Ahead of Deadline

Updated Category News Views 188

UroGen Pharma Investors: Key Deadline Approaching Attention UroGen Pharma Ltd. investors! The clock is ticking on an important opportunity that you won't want to miss. The class action lawsuit involving UroGen Pharma (URGN) has reached a crucial stage and if you've been affected, now is the time to act. The deadline for an essential step in the lawsuit is coming up on...

Continue Reading
Enhancing Workplace Safety with Voxel's Innovative Impact Boards

Updated Category News Views 121

Revolutionizing Workplace Safety with AI Insights In today's fast-paced work environment, ensuring safety and operational efficiency is paramount. Voxel, an Applied AI company dedicated to transforming workplace safety, has launched its latest innovation: the Impact Boards. These boards are designed to provide tailored, shift-specific safety insights that enable teams to...

Continue Reading
First Quantum Minerals Expands Senior Notes Offering Leadership

Updated Category News Views 112

First Quantum Minerals Expands Senior Notes Offering In a significant development, First Quantum Minerals Ltd. (TSX: FM) has announced a remarkable $1 billion offering of senior notes, demonstrating its strong standing in the mining industry. The company has increased the original offering amount from $750 million to $1 billion, clearly indicating investor confidence and...

Continue Reading